An estimated 30 million Americans are now taking GLP-1 receptor agonists for weight loss and type 2 diabetes, but a converging body of research suggests the medications’ appetite-suppressing power comes with a hidden cost. Major reviews from Harvard, the University of Copenhagen, Northwestern University and Ohio State University have identified widespread shortfalls in vitamin B12, protein, fibre and vitamin D among users — deficiencies that clinicians say could undermine the very health gains the drugs promise.
The appetite trap: how weight loss drives malnutrition
The mechanism that makes GLP-1s so effective — a dramatic reduction in hunger — is also the root of the problem. Patients simply stop eating enough to meet basic nutritional requirements. An August review led by researchers at the Harvard T.H. Chan School of Public Health and the University of Copenhagen found that 43 per cent of GLP-1 users consume inadequate protein, while fibre intake has plummeted to levels that trigger nausea, bloating and constipation. That gastrointestinal distress, the authors noted, can create a vicious cycle in which patients eat even less.
“As GLP-1 prescriptions reach millions of patients across diverse and often under-resourced clinical settings, integrating nutrition into this care model is not just advisable; it is urgent,” the Harvard and Copenhagen team stressed.
Protein and fibre are not optional extras. The Mayo Clinic emphasises that both are essential for maintaining lean muscle mass, stabilising blood sugar and sustaining a healthy weight long term. Without them, the metabolic benefits of the drugs may prove fleeting.
B12 crisis: ten million Americans at risk
Vitamin B12 deficiency has emerged as a particular concern. The vitamin, found almost exclusively in animal products, protects nerve function and supports red blood cell formation. Researchers at Ohio State University calculate that roughly 10 million Americans already fall below the recommended threshold — a figure set to climb as GLP-1 use expands. Patients following plant-based diets face compounded risk, since the drugs further shrink the already limited B12 in their dietary intake.
Children and adolescents: a generation in the crosshairs
The paediatric data are arguably the most alarming. Prescribing of GLP-1s to children under 12 has surged 300-fold in seven years. A September study from Northwestern University tracked 10- to 17-year-olds on the medications for a year and found nearly one in six developed a nutrient deficiency. Vitamin D topped the list.
“Nutrients such as vitamin D, iron, and calcium are of particular concern during adolescence, when deficiencies may have lasting implications for skeletal health and overall development,” the study authors wrote.
Vitamin D is critical for bone mineralisation during the peak bone-building years. A shortfall now could translate into osteoporosis decades earlier than expected.
Adults not spared: bone health under threat
The deficit extends well beyond childhood. A January review of more than 480,000 adults on GLP-1 therapy showed 13.6 per cent were vitamin D deficient after 12 months. For middle-aged and older patients — already facing natural bone density decline — the added depletion is a recipe for fractures and frailty.
The Cleveland Clinic warns that untreated nutrient deficiencies, regardless of cause, can lead to soft bones, stunted growth and a cascade of systemic effects. Clinicians should watch for weakness, fatigue, inattention, dry skin or rashes, hair loss, brittle hair, recurrent infections, low body temperature and reduced heart rate — all potential red flags.
Why it Matters
GLP-1 drugs have transformed the treatment landscape for obesity and diabetes, offering millions a lifeline they never had before. But the emerging evidence demands a paradigm shift: prescribing cannot stop at the injection. Without routine nutritional screening, targeted supplementation and dietary counselling built into the standard of care, we risk trading one epidemic for another — swapping metabolic disease for a silent wave of malnutrition that weakens bones, damages nerves and erodes the very vitality these medicines were meant to restore.